US M&A and equity raisings

3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

62 deals · US$14bndisclosed · Biotech · Clear

Columns
US M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Feb 2026 Sensei Biotherapeutics ––PlacementPending200.0Biotech+2 Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager)
Feb 2026 Liminatus Pharma ––Follow-on offeringAnnounced4.0Biotech+2 Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager)
Feb 2026 Agomab Therapeutics NV ––IPOAnnounced200.0Biotech+2 Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager)
Feb 2026 Eikon Therapeutics ––IPOAnnounced381.2Oncology+1 Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager)
Feb 2026 Veradermics ––IPOAnnounced256.3Dermatology+2 Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager)
Feb 2026 Perspective Therapeutics ––Follow-on offeringAnnounced175.0Radiopharmaceuticals+2 Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager)
Jan 2026 Polaryx Therapeutics ––Direct listingCompleted–Biotech+1 Maxim Group (issuer)Gibson Dunn (issuer)Brownstein Hyatt Farber Schreck (issuer)
Jan 2026 Aktis Oncology ––IPOListed317.7Biotech+2 Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager)
Dec 2025 Apimeds Pharmaceuticals US ––ConvertibleCompleted10.9Pharma+1 Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager)
– Lakewood-Amedex Biotherapeutics ––Direct listingAnnounced–Biotech+1 RBW Capital Partners (issuer)
– Silexion Therapeutics Corp ––Follow-on offeringAnnounced2.5Biotech+2 Conyers (issuer)Greenberg Traurig (issuer)H.C. Wainwright & Co. (lead manager)Ellenoff Grossman & Schole (lead manager)
– Vogenx ––IPOAnnounced81.3Biotech Smith Anderson (issuer)JonesTrading (lead manager)Sichenzia Ross Ference Carmel (lead manager)

Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built